No Priors Ep. 121 | With Chai Discovery Co-Founders Jack Dent and Joshua Meier

Chai Discovery's co-founders discuss Chai 2, their new generative AI platform for antibody design. It achieves a nearly 20% hit rate from just 20 computational attempts, a 100-fold improvement over previous methods, signaling a shift from drug discovery to drug engineering.